History | Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer | Guidance | NICE

History

Documents created during the development process.

Expected publication

Equality Impact Assessment (Guidance development) (PDF 155 KB)

Published:

01 July 2020

Declaration of interests

Register of interests (PDF 134 KB)

Published:

01 July 2020

Final draft guidance

Final draft guidance
Final appraisal document (PDF 255 KB)

Published:

22 May 2020
Committee papers - FAD (PDF 1.16 MB)

Published:

22 May 2020

Draft guidance

Draft guidance
Appraisal consultation document (online commenting)
Appraisal consultation document (PDF version) (PDF 293 KB)

Published:

03 October 2019
Committee papers (PDF 9.59 MB)

Published:

03 October 2019
Public committee slides (PDF 859 KB)

Published:

03 October 2019

Invitation to participate

Final scope (PDF 225 KB)

Published:

14 January 2019
Final stakeholder list (PDF 260 KB)

Published:

14 January 2019
NICE's response to comments on the draft scope and provisional stakeholder list (PDF 281 KB)

Published:

14 January 2019
Equality impact assessment (Scoping) (PDF 175 KB)

Published:

15 January 2019

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

Draft scope post referral (PDF 315 KB)

Published:

26 November 2018
Draft matrix post referral (PDF 259 KB)

Published:

26 November 2018